ARVEESpecialty Chemicals
Arvee Laboratories India Ltd — Profit & Loss Statement
₹133.86
-4.98%
Arvee Laboratories India Ltd Profit & Loss Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.02 Cr | -95330.34 | 0.05 Cr | 0.04 Cr |
| Tax Rate For Calcs | 0.30 | 0.33 | 0.25 | 0.29 |
| Normalized EBITDA | 3.44 Cr | 8.56 Cr | 5.97 Cr | 6.47 Cr |
| Total Unusual Items | 0.08 Cr | -0.03 Cr | 0.18 Cr | 0.13 Cr |
| Total Unusual Items Excluding Goodwill | 0.08 Cr | -0.03 Cr | 0.18 Cr | 0.13 Cr |
| Net Income From Continuing Operation Net Minority Interest | 1.05 Cr | 4.12 Cr | 2.57 Cr | 2.68 Cr |
| Reconciled Depreciation | 1.50 Cr | 2.08 Cr | 2.38 Cr | 2.47 Cr |
| Reconciled Cost Of Revenue | 18.76 Cr | 43.97 Cr | 25.88 Cr | 32.84 Cr |
| EBITDA | 3.52 Cr | 8.53 Cr | 6.15 Cr | 6.60 Cr |
| EBIT | 2.02 Cr | 6.45 Cr | 3.76 Cr | 4.13 Cr |
| Net Interest Income | 0.11 Cr | -0.19 Cr | -0.11 Cr | -0.29 Cr |
| Interest Expense | 0.19 Cr | 0.29 Cr | 0.31 Cr | 0.49 Cr |
| Interest Income | 0.36 Cr | 0.20 Cr | 0.27 Cr | 0.28 Cr |
| Normalized Income | 1.00 Cr | 4.14 Cr | 2.44 Cr | 2.59 Cr |
| Net Income From Continuing And Discontinued Operation | 1.05 Cr | 4.12 Cr | 2.57 Cr | 2.68 Cr |
| Total Expenses | 28.86 Cr | 56.04 Cr | 36.69 Cr | 43.34 Cr |
| Rent Expense Supplemental | 0.38 Cr | 0.38 Cr | 0.35 Cr | 0.18 Cr |
| Diluted Average Shares | 1.10 Cr | 1.10 Cr | 1.10 Cr | 0.85 Cr |
| Basic Average Shares | 1.10 Cr | 1.10 Cr | 1.10 Cr | 0.85 Cr |
| Diluted EPS | 0.95 | 3.74 | 2.34 | 3.24 |
| Basic EPS | 0.95 | 3.74 | 2.34 | 3.24 |
| Diluted NI Availto Com Stockholders | 1.05 Cr | 4.12 Cr | 2.57 Cr | 2.68 Cr |
| Net Income Common Stockholders | 1.05 Cr | 4.12 Cr | 2.57 Cr | 2.68 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 1.05 Cr | 4.12 Cr | 2.57 Cr | 2.68 Cr |
| Net Income Including Noncontrolling Interests | 1.05 Cr | 4.12 Cr | 2.57 Cr | 2.68 Cr |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Continuous Operations | 1.05 Cr | 4.12 Cr | 2.57 Cr | 2.68 Cr |
| Tax Provision | 0.78 Cr | 2.05 Cr | 0.88 Cr | 0.96 Cr |
| Pretax Income | 1.83 Cr | 6.17 Cr | 3.45 Cr | 3.64 Cr |
| Other Non Operating Income Expenses | 0.01 Cr | 65920.00 | 83770.00 | 76830.00 |
| Special Income Charges | 0.01 Cr | -0.04 Cr | 0.06 Cr | -0.17 Cr |
| Other Special Charges | -0.06 Cr | -10050.00 | -0.07 Cr | 0.02 Cr |
| Write Off | 0.05 Cr | 0.04 Cr | 85220.00 | 0.15 Cr |
| Net Non Operating Interest Income Expense | 0.11 Cr | -0.19 Cr | -0.11 Cr | -0.29 Cr |
| Total Other Finance Cost | 0.06 Cr | 0.10 Cr | 0.06 Cr | 0.08 Cr |
| Interest Expense Non Operating | 0.19 Cr | 0.29 Cr | 0.31 Cr | 0.49 Cr |
| Interest Income Non Operating | 0.36 Cr | 0.20 Cr | 0.27 Cr | 0.28 Cr |
| Operating Income | 1.49 Cr | 5.24 Cr | 3.00 Cr | 3.81 Cr |
| Operating Expense | 10.09 Cr | 12.07 Cr | 10.81 Cr | 10.49 Cr |
| Other Operating Expenses | 0.01 Cr | 78460.00 | 0.05 Cr | 0.05 Cr |
| Depreciation And Amortization In Income Statement | 1.50 Cr | 2.08 Cr | 2.32 Cr | 2.41 Cr |
| Amortization | 79020.00 | 85500.00 | 85500.00 | 85500.00 |
| Depreciation Income Statement | 1.49 Cr | 2.07 Cr | 2.31 Cr | 2.40 Cr |
| Selling General And Administration | 2.27 Cr | 3.53 Cr | 2.67 Cr | 2.55 Cr |
| Selling And Marketing Expense | 0.70 Cr | 2.10 Cr | 1.62 Cr | 1.82 Cr |
| General And Administrative Expense | 1.57 Cr | 1.44 Cr | 1.05 Cr | 0.73 Cr |
| Rent And Landing Fees | 0.38 Cr | 0.38 Cr | 0.35 Cr | 0.18 Cr |
| Gross Profit | 11.58 Cr | 17.31 Cr | 13.81 Cr | 14.30 Cr |
| Cost Of Revenue | 18.76 Cr | 43.97 Cr | 25.88 Cr | 32.84 Cr |
| Total Revenue | 30.34 Cr | 61.28 Cr | 39.69 Cr | 47.14 Cr |
| Operating Revenue | 30.34 Cr | 61.28 Cr | 39.69 Cr | 47.14 Cr |
| Research And Development | — | — | 0.00 | 0.00 |
| Impairment Of Capital Assets | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Arvee Laboratories India Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.